Terms: = Lymphoma AND TRIM27, DASS-46L4_6, RFP, 5987, ENSG00000234495, RNF76
41709 results:
1. IL-15 gene mutation as a molecular risk factor in acute lymphoid leukemia.
Mohammed SI; Hassan KM; Azeez DM; Qadir FA; Salihi AB
Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):10-17. PubMed ID: 38814240
[TBL] [Abstract] [Full Text] [Related]
2. A new mode for the diagnosis of angioimmunoblastic T-cell lymphoma.
Wang H; Han X; Nie Y; Zhang C; Li J; Yang R; Jiang Y
Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):155-160. PubMed ID: 38814221
[TBL] [Abstract] [Full Text] [Related]
3. Investigating the physiological role of S199A and S199D mutants of PHF6 protein in T-cell acute lymphoblastic leukemia.
Erdoğan G; Özeş ON; Küpesiz A; Yoldaş ŞB
Turk J Med Sci; 2023; 53(5):1234-1243. PubMed ID: 38812997
[TBL] [Abstract] [Full Text] [Related]
4. [Effect of Shoutai Pills on expression of key glycolytic proteins and apoptosis related factors at maternal fetal interface in mouse model of threatened abortion with syndrome of kidney deficiency].
Song YJ; Li DD; Lyu JF; Jiang M; DU HL
Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(8):2169-2177. PubMed ID: 38812232
[TBL] [Abstract] [Full Text] [Related]
5. [Effects of plumbagin on proliferation and apoptosis of human hepatocellular carcinoma cells based on CKB/p53 signaling pathway].
Zhou FL; Yuan B; Ye YX; Deng SY; Ma J; Liu H; Ma YZ; Wei YF
Zhongguo Zhong Yao Za Zhi; 2024 May; 49(9):2345-2354. PubMed ID: 38812135
[TBL] [Abstract] [Full Text] [Related]
6. A retrospective analysis of the incidence and risk factors of perioperative urinary tract infections after total hysterectomy.
Cao X; Tu Y; Zheng X; Xu G; Wen Q; Li P; Chen C; Yang Q; Wang J; Li X; Yu F
BMC Womens Health; 2024 May; 24(1):311. PubMed ID: 38811924
[TBL] [Abstract] [Full Text] [Related]
7. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.
Kadia TM; Huang M; Pemmaraju N; Abbas HA; Ly C; Masarova L; Yilmaz M; Lyu MA; Zeng K; Sadeghi T; Cook R; DiNardo CD; Daver N; Issa GC; Jabbour E; Borthakur G; Jain N; Garcia-Manero G; Parmar S; Flowers C; Kantarjian H; Verstovsek S
NEJM Evid; 2024 Jun; 3(6):EVIDoa2300362. PubMed ID: 38804782
[TBL] [Abstract] [Full Text] [Related]
8. [Prognostic analysis of childhood T-lymphoblastic lymphoma treated with leukemia regimen].
Hou SM; Shao JB; Li H; Zhang N; Zhu JS; Wang D; Fu P
Zhongguo Dang Dai Er Ke Za Zhi; 2024 May; 26(5):469-475. PubMed ID: 38802906
[TBL] [Abstract] [Full Text] [Related]
9. General anaesthetics reduce acute lymphoblastic leukaemia malignancies
Jiang C; Gonzalez-Anton S; Li X; Mi E; Wu L; Zhao H; Zhang G; Lu A; Lo Celso C; Ma D
F1000Res; 2022; 11():1491. PubMed ID: 38798305
[TBL] [Abstract] [Full Text] [Related]
10. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Dupuis J; Bachy E; Morschhauser F; Cartron G; Fukuhara N; Daguindau N; Casasnovas RO; Snauwaert S; Gressin R; Fox CP; d'Amore FA; Staber PB; Tournilhac O; Bouabdallah K; Thieblemont C; André M; Rai S; Ennishi D; Gkasiamis A; Nishio M; Fornecker LM; Delfau-Larue MH; Sako N; Mule S; de Leval L; Gaulard P; Tsukasaki K; Lemonnier F
Lancet Haematol; 2024 Jun; 11(6):e406-e414. PubMed ID: 38796193
[TBL] [Abstract] [Full Text] [Related]
11. BIA-ALCL and BIA-SCC: Updates on Clinical Features and Genetic Mutations for Latest Recommendations.
D'Orsi G; Giacalone M; Calicchia A; Gagliano E; Vannucchi L; Vanni G; Buonomo OC; Cervelli V; Longo B
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38792976
[TBL] [Abstract] [Full Text] [Related]
12. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
Kilickap S; Ozturk A; Karadurmus N; Korkmaz T; Yumuk PF; Cicin I; Paydas S; Cilbir E; Sakalar T; Uysal M; Yesil Cinkir H; Uskent N; Demir N; Sakin A; Dursun OU; Aver B; Turhal NS; Keskin S; Tural D; Eralp Y; Bugdayci Basal F; Yasar HA; Sendur MAN; Demirci U; Cubukcu E; Karaagac M; Cakar B; Tatli AM; Yetisyigit T; Urvay S; Gursoy P; Oyan B; Turna ZH; Isikdogan A; Olmez OF; Yazici O; Cabuk D; Seker MM; Unal OU; Meydan N; Okutur SK; Tunali D; Erman M;
Medicine (Baltimore); 2024 May; 103(21):e37972. PubMed ID: 38787994
[TBL] [Abstract] [Full Text] [Related]
13. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163
[TBL] [Abstract] [Full Text] [Related]
14. FAT1 inhibits the proliferation of DLBCL cells via increasing the m
Wang TL; Miao XJ; Shuai YR; Sun HP; Wang X; Yang M; Zhang N
Sci Rep; 2024 May; 14(1):11836. PubMed ID: 38782965
[TBL] [Abstract] [Full Text] [Related]
15. DEAD-box helicase 17 (DDX17) protects cardiac function by promoting mitochondrial homeostasis in heart failure.
Yan M; Gao J; Lan M; Wang Q; Cao Y; Zheng Y; Yang Y; Li W; Yu X; Huang X; Dou L; Liu B; Liu J; Cheng H; Ouyang K; Xu K; Sun S; Liu J; Tang W; Zhang X; Man Y; Sun L; Cai J; He Q; Tang F; Li J; Shen T
Signal Transduct Target Ther; 2024 May; 9(1):127. PubMed ID: 38782919
[TBL] [Abstract] [Full Text] [Related]
16. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
Li X; Wu D; Tang J; Wu Y
J Cancer Res Clin Oncol; 2024 May; 150(5):271. PubMed ID: 38780840
[TBL] [Abstract] [Full Text] [Related]
17. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
Salem AH; Menon RM
Clin Transl Sci; 2024 May; 17(5):e13807. PubMed ID: 38778732
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of the prevalence of Aeromonas spp., Campylobacter spp., and Clostridioides difficile in immunocompromised children with diarrhea.
Heydari H; Iranikhah A; Ghasemi A; Mohammadbeigi A; Sadat-Mirei SA; Shams S; Kermani S
BMC Infect Dis; 2024 May; 24(1):512. PubMed ID: 38778271
[TBL] [Abstract] [Full Text] [Related]
19. CAR T-Cell Immunotherapy in Minority Patients with lymphoma.
Ghilardi G; Williamson S; Pajarillo R; Paruzzo L; Chen L; Grady C; Doucette A; Nemecek E; Gabrielli G; Barta SK; Svoboda J; Chong EA; Yelton R; Nasta SD; Landsburg DJ; Ugwuanyi O; Chen AI; Schachter L; White G; Ballard HJ; Weber E; Curley C; Porter DL; Garfall AL; Hwang WT; Guerra CE; Maziarz RT; Schuster SJ; Ruella M
NEJM Evid; 2024 Apr; 3(4):EVIDoa2300213. PubMed ID: 38776868
[TBL] [Abstract] [Full Text] [Related]
20. A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL.
Wang X; Deng Y; He G; Lai S; Li Y; Zhang S; He Y; Han Y; Zhang L; Su Y; Liu F; Yi H
Hematology; 2024 Dec; 29(1):2356300. PubMed ID: 38776229
[TBL] [Abstract] [Full Text] [Related]
[Next]
